Inflammatorisches Immunrekonstitutionssyndrom nach Natalizumab-induzierter progressiver multifokaler Leukenzephalopathie

Literatur

• 1 Sahraian M A, Radue E W, Eshaghi A et al. Progressive Multifocal Leukencephalopathy: a review of the neuroimaging features and differential diagnosis.  Eur J Neurol. 2011;  . Epub ahead of print, 2011; DOI: 10.1111/j.1468 – 1331.2011.03597.x
• 2 Aksamit A J. Review of progressive multifocal leukencephalopathy and natalizumab.  Neurologist. 2006;  12(6) 293-298
• 3 Metz I, Radue E W, Oterino A et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.  Acta Neuropathol. 2011;  . Epub ahead of print, 2011; DOI 10.1007/s00401 – 011 – 0900 – 5
• 4 Clifford D B, DeLuca A, Simpson D M et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lesions from 28 cases.  Lancet Neurol. 2010;  9 438-446
• 5 Hardova E, Galetta S, Hutchinson M et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.  Lancet Neurol. 2009;  8 254-260
• 6 Yousry T A, Major E O, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukencephalopathy.  N Eng J Med. 2006;  354 924-933
• 7 Wenning W, Haghikia A, Laubenberger J et al. Treatment of progressive Multifocal Leukencephalopathy Associated with Natalizumab.  N Engl J Med. 2009;  361 1075-1080